ERBB2 and gastric cancer: However, one strength of these exploratory analyses is that the data are from a robustly designed clinical trial of T-DXd compared with chemotherapy in patients with HER2+ advanced gastric cancer; the analyses presented are from patients in the T-DXd arm of the primary cohort as well as from those in the two exploratory cohorts, all of whom received T-DXd4.